{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:29:28Z","timestamp":1790040568617,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515140148"],"award-info":[{"award-number":["2023A1515140148"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515110144"],"award-info":[{"award-number":["2024A1515110144"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.phrs.2026.108235","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:32:25Z","timestamp":1778167945000},"page":"108235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Overexpression of HIF-1\u03b1 via small activating RNA enhances CAR-T cell function in hypoxic microenvironments"],"prefix":"10.1016","volume":"229","author":[{"given":"Na","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Asad","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songshan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqra","family":"Ajmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.phrs.2026.108235_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.phrs.2026.108235_bib2","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","article-title":"Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment","volume":"18","author":"Liu","year":"2021","journal-title":"Cell Mol. Immunol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108235_bib3","first-page":"301","article-title":"Advances in strategies to improve the immunotherapeutic efficacy of chimeric antigen receptor-T cell therapy for lymphoma","volume":"22","author":"Yu","year":"2025","journal-title":"Cancer Biol. Med"},{"issue":"1","key":"10.1016\/j.phrs.2026.108235_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phrs.2026.108235_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz","year":"2015","journal-title":"Hypoxia (Auckl. )"},{"issue":"12","key":"10.1016\/j.phrs.2026.108235_bib6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108235_bib7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","article-title":"Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors","volume":"84","author":"Zhu","year":"2024","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.phrs.2026.108235_bib8","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.celrep.2017.08.071","article-title":"Culturing CTLs under hypoxic conditions enhances their cytolysis and improves their anti-tumor function","volume":"20","author":"Gropper","year":"2017","journal-title":"Cell Rep."},{"issue":"19","key":"10.1016\/j.phrs.2026.108235_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914541","article-title":"Thrombotic Alterations under Perinatal Hypoxic Conditions: HIF and Other Hypoxic Markers","volume":"24","author":"Berna-Erro","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2026.108235_bib10","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cmet.2020.08.002","article-title":"The Role of HIF in Immunity and Inflammation","volume":"32","author":"McGettrick","year":"2020","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.phrs.2026.108235_bib11","article-title":"Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy","volume":"10","author":"Jenkins","year":"2021","journal-title":"Antibodies (Basel)"},{"issue":"1","key":"10.1016\/j.phrs.2026.108235_bib12","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1038\/s41467-023-42634-3","article-title":"Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1\u03b1-mediated glycolytic reprogramming","volume":"14","author":"Wu","year":"2023","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.phrs.2026.108235_bib13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.cell.2011.07.033","article-title":"Control of T(H)17\/T(reg) balance by hypoxia-inducible factor 1","volume":"146","author":"Dang","year":"2011","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.phrs.2026.108235_bib14","first-page":"460","article-title":"The mechanisms and clinical significance of CD8(+) T cell exhaustion in anti-tumor immunity","volume":"22","author":"Zhong","year":"2025","journal-title":"Cancer Biol. Med"},{"issue":"4","key":"10.1016\/j.phrs.2026.108235_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cells8040371","article-title":"Cross-Kingdom Small RNAs Among Animals, Plants and Microbes","volume":"8","author":"Zeng","year":"2019","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.phrs.2026.108235_bib16","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/wrna.90","article-title":"Small RNA and transcriptional upregulation","volume":"2","author":"Portnoy","year":"2011","journal-title":"Wiley Inter. Rev. RNA"},{"issue":"1","key":"10.1016\/j.phrs.2026.108235_bib17","doi-asserted-by":"crossref","first-page":"9341","DOI":"10.1038\/s41598-023-36523-4","article-title":"RNA activation in ticks","volume":"13","author":"Kwofie","year":"2023","journal-title":"Sci. Rep."},{"issue":"24","key":"10.1016\/j.phrs.2026.108235_bib18","doi-asserted-by":"crossref","first-page":"10182","DOI":"10.1158\/0008-5472.CAN-10-2414","article-title":"Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration","volume":"70","author":"Wang","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2026.108235_bib19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025028683","article-title":"Pooled CAR-T screening in nonhuman primates identifies designs with enhanced proliferation, trafficking, and persistence","author":"Maynard","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.phrs.2026.108235_bib20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108235_bib21","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41423-025-01304-8","article-title":"Transitioning from native to synthetic receptors: broadening T-cell engineering and beyond","volume":"22","author":"Yu","year":"2025","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.phrs.2026.108235_bib22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.omtm.2017.12.003","article-title":"Enhanced expression of anti-CD19 chimeric antigen receptor in piggybac transposon-engineered T Cells","volume":"8","author":"Morita","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.phrs.2026.108235_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.biocel.2018.02.002","article-title":"Small activating RNA induced expression of VHL gene in renal cell carcinoma","volume":"97","author":"Kang","year":"2018","journal-title":"Int J. Biochem Cell Biol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108235_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/cr.2016.22","article-title":"saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription","volume":"26","author":"Portnoy","year":"2016","journal-title":"Cell Res"},{"issue":"9","key":"10.1016\/j.phrs.2026.108235_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091797","article-title":"Human CD3+ T-Cells with the Anti-ERBB2 chimeric antigen receptor exhibit efficient targeting and induce apoptosis in ERBB2 overexpressing breast cancer cells","volume":"18","author":"Munisvaradass","year":"2017","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108235_bib26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymthe.2017.10.012","article-title":"Retroviral and lentiviral safety analysis of gene-modified T cell products and infused HIV and oncology patients","volume":"26","author":"Marcucci","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.phrs.2026.108235_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.omtm.2021.02.023","article-title":"Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells","volume":"21","author":"Tay","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"10","key":"10.1016\/j.phrs.2026.108235_bib28","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1016\/j.ymthe.2024.08.028","article-title":"Intrinsic ADRB2 inhibition improves CAR-T cell therapy efficacy against prostate cancer","volume":"32","author":"Ajmal","year":"2024","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2026.108235_bib29","first-page":"266","article-title":"Modeling Physiological Events in 2D vs. 3D Cell Culture","volume":"32","author":"Duval","year":"2017","journal-title":"Physiol. (Bethesda)"},{"issue":"7971","key":"10.1016\/j.phrs.2026.108235_bib30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"issue":"41","key":"10.1016\/j.phrs.2026.108235_bib31","doi-asserted-by":"crossref","first-page":"E2784","DOI":"10.1073\/pnas.1202366109","article-title":"Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa","volume":"109","author":"Clambey","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2026.108235_bib32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","article-title":"The hypoxic tumour microenvironment","volume":"7","author":"Petrova","year":"2018","journal-title":"Oncogenesis"},{"issue":"11","key":"10.1016\/j.phrs.2026.108235_bib33","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/ni.2714","article-title":"Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen","volume":"14","author":"Doedens","year":"2013","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108235_bib34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1158\/2326-6066.CIR-22-0099","article-title":"PHD2 constrains antitumor CD8+ T-cell Activity","volume":"11","author":"Bisilliat Donnet","year":"2023","journal-title":"Cancer Immunol. Res"},{"issue":"6","key":"10.1016\/j.phrs.2026.108235_bib35","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.immuni.2015.05.016","article-title":"E3 Ubiquitin Ligase VHL regulates hypoxia-inducible factor-1\u03b1 to maintain regulatory t cell stability and suppressive capacity","volume":"42","author":"Lee","year":"2015","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.phrs.2026.108235_bib36","first-page":"1549","article-title":"The efficacy of third generation anti\u2011HER2 chimeric antigen receptor T cells in combination with PD1 blockade against malignant glioblastoma cells","volume":"42","author":"Shen","year":"2019","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108235_bib37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41392-021-00462-1","article-title":"Nanobody-based chimeric antigen receptor T cells designed by CRISPR\/Cas9 technology for solid tumor immunotherapy","volume":"6","author":"Mo","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"16","key":"10.1016\/j.phrs.2026.108235_bib38","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1073\/pnas.1817147116","article-title":"Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice","volume":"116","author":"Xie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.phrs.2026.108235_bib39","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2174\/138920110791591463","article-title":"Defining features and exploring chemical modifications to manipulate RNAa activity","volume":"11","author":"Place","year":"2010","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108235_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrc2966","article-title":"RNA interference in the clinic: challenges and future directions","volume":"11","author":"Pecot","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108235_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"2 Pt C","key":"10.1016\/j.phrs.2026.108235_bib42","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.molimm.2015.07.027","article-title":"Metabolic regulation of T cell differentiation and function","volume":"68","author":"Park","year":"2015","journal-title":"Mol. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108235_bib43","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.phrs.2026.108235_bib44","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.immuni.2016.07.008","article-title":"Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 Are an Early Driver of CD8+ T Cell Exhaustion","volume":"45","author":"Bengsch","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.phrs.2026.108235_bib45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","article-title":"Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development","volume":"36","author":"van der Windt Gerritje","year":"2012","journal-title":"Immunity"},{"issue":"35","key":"10.1016\/j.phrs.2026.108235_bib46","doi-asserted-by":"crossref","first-page":"14336","DOI":"10.1073\/pnas.1221740110","article-title":"CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability","volume":"110","author":"van der Windt","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.phrs.2026.108235_bib47","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.4049\/jimmunol.180.7.4476","article-title":"Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways","volume":"180","author":"Jacobs","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108235_bib48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol. Res"},{"issue":"7851","key":"10.1016\/j.phrs.2026.108235_bib49","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","article-title":"CTLA-4 blockade drives loss of T(reg) stability in glycolysis-low tumours","volume":"591","author":"Zappasodi","year":"2021","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.phrs.2026.108235_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082312","article-title":"CTLA-4 mediates inhibitory function of mesenchymal stem\/stromal cells","volume":"19","author":"Gaber","year":"2018","journal-title":"Int J. Mol. Sci."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:04:54Z","timestamp":1783170294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826001507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"alternative-id":["S1043661826001507"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108235","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overexpression of HIF-1\u03b1 via small activating RNA enhances CAR-T cell function in hypoxic microenvironments","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108235"}}